Risk of Psychiatric Worsening With GLP ‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression
Main finding · SuicidalityResult — go to the resultHazard ratio 0.88 95% CI 0.74–1.05Authors' conclusion
In patients with type 2 diabetes and treated depression, we did not detect increased short-term documented suicidality after GLP-1 RA initiation compared with SGLT2i initiation and observed less subsequent treatment intensification.
Study context
- Population
- Patients with T2D, depression and antidepressant treatment within 6 months before index, TriNetX networkpropensity-score matched
- Participants
- 34,761 vs 34,761
- Exposure
- GLP-1 RA vs SGLT2i initiation
- GLP-1 RAn = 34,761
- SGLT2in = 34,761reference
- Outcome
- Suicidality and antipsychotic use
- Follow-up
- 1 year
Methodological detailsactive-comparator, new-user, 1:1 propensity score matching, electronic health records (TriNetX)
- Active-comparator
- New-user
- 1:1 propensity score matching
- Electronic health records (TriNetX)
Main finding
Suicidality
Hazard ratio
0.88
95% CI 0.74–1.05
GLP-1 RAvs SGLT2i
HR 0.88 (95% CI 0.74–1.05)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Antipsychotic use (co-primary outcome)GLP-1 RAvs SGLT2i | 0.86 (0.82–0.90) | |
| All-cause mortality | 0.64 (0.58–0.71) | |
| 0.512Hazard ratio (log scale) |
| Outcome | Absolute risk difference (%) |
|---|---|
| Antipsychotic use (co-primary outcome)GLP-1 RA vs SGLT2i | −1.4 |
Sensitivity analyses
- Findings were consistent across sensitivity analyses
Original publication
Risk of Psychiatric Worsening With GLP ‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression. Diabetes Obes Metab. Published 28 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →